With something as essential as breath, every moment matters. Early detection saves lives. Let’s keep pushing for awareness and action. #WorldLungCancerDay #EarlyDetection #LungCancerAwareness #CyPathLung

Stratification isn’t just a clinical tool; it’s a strategic advantage in delivering precise, patient-centered care. See what physicians are saying: cypathlung.com #CyPathLung #LungCancer #EarlyDetection #PatientCare #PhysicianHighlights

Every year, millions of Americans face a higher risk for lung cancer, often without knowing it. Do you know how many people in the U.S. are considered high risk annually, according to the CDC?

Life With Cancer: Aging is the privilege that you hope for. #cancer #lungcancer #cancersucks

When a CyPath® Lung sample delay arose, our team jumped into action, ensuring safe, timely delivery to the lab. When patient care is at the heart of our team, it can’t skip a beat. ❤️ #CyPathLung #LungCancer #PrecisionPathology #Teamwork #PatientCare

Looking forward to connecting at AABIP 2025 Conference 8/14. Visit Booth 44 to learn how physicians use CyPath® Lung as a noninvasive diagnostic tool to support early detection of lung cancer and improve patient care. #CyPathLung #LungCancer #EarlyDetection #AABIP2025

July kicked off Q3 with a 72% surge in CyPath® Lung tests, detecting lung cancer early when treatment works best. With expansion into new markets & the VA, we project 3X YoY revenue growth in 2025. $BIAF 🔗 bit.ly/72completed #CyPathLung #LungCancer #InvestorNews

Why are investors paying closer attention to bioAffinity Technologies $BIAF? Because it checks the boxes: clinical validation, insurance reimbursement, commercial momentum, and health system impact. CyPath® Lung is more than a test: it’s a platform for building long-term diagnostic value.

Wrapped up #AABIP2025 sharing how CyPath® Lung helps detect lung cancer early, when treatment is most effective. Grateful for the conversations, collaborations & commitment to advancing lung health. #LungCancer #EarlyDetection #CyPathLung #PatientCare

We’re excited to welcome Roberto Rios, CPA, and John J. Oppenheimer, M.D., to our Board of Directors to help drive growth and innovation at bioAffinity. $BIAF 🔗bit.ly/41Jj4YZ #bioAffinity #LungHealth #LungCancer #BoardofDirectors

Our CSO, Dr. William Bauta, will present at #ACS2025: Silencing CD320 & LRP2 is selectively toxic to cancer cells. siRNA silencing of these receptors shows targeted cancer cell death while sparing normal cells. Aug 20 | 5–7 PM CST | #RNAi #Oncology #bioAffinity

Every person with COPD deserves access to education and support. Share this post and help us reach those who need it most. Lung.org/COPD

We are honored to be featured in U.S. Medicine. New issue includes a story on the economic impact of our #CyPathLung test for #lungcancer. See our press release at bit.ly/47tdq12 See the US Medicine story at bit.ly/41XHLRR #innovation #pulmonology #veterans

Ground-glass nodules often mean years of “watchful waiting.” In a new case, CyPath® Lung delivered actionable results that led to timely lung cancer diagnosis and treatment. Read more➡️ bit.ly/3JNK181 #LungCancer #Diagnostics #CyPathLung